PainReform Ltd., an Israeli start up that is aiming to develop non-opioid post-surgery pain treatments, set terms for its initial public offering on Monday, with plans to offer 2.55 million units priced at…
$8 to $10 each.
Each unit will consist of one ordinary share and a warrant to purchase a share, the company said in a regulatory filing. The company has applied to list on Nasdaq under the ticker “PRFX.”
Maxim Group and Joseph Gunnar & Co. are underwriting the deal.
Proceeds will be used to fund clinical trials, and for general corporate purposes.
“Our proprietary extended release drug-delivery system is designed to provide an…
Continue reading at MARKETWATCH.com
